Table 2.
Expression of ToPo II, MRP, GST-π and their relationship with clinicopathological factors
| Clinicopatho logic Features | Cases | ToPo II | MRP | GST-π | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
|
| ||||||||||
| + (%) | χ2 | P | + (%) | χ2 | P | + (%) | χ2 | P | ||
| Sex | ||||||||||
| Male | 77 | 54 (70.1%) | 29 (37.7%) | 46 (59.7%) | ||||||
| Female | 42 | 34 (81.0%) | 1.65 | 0.198 | 2 (52.4%) | 2.40 | 0.121 | 15 (35.7%) | 6.27 | 0.012 |
| Age | ||||||||||
| ≤50 y | 33 | 24 (72.7%) | 16 (48.5%) | 14 (42.4%) | ||||||
| >50 y | 86 | 64 (74.4%) | 0.03 | 0.851 | 35 (40.7%) | 0.59 | 0.442 | 47 (54.7%) | 1.42 | 0.232 |
| Tumor size | ||||||||||
| ≥5 cm | 76 | 59 (77.6%) | 35 (46.1%) | 40 (52.6%) | ||||||
| <5 cm | 43 | 29 (67.4%) | 1.48 | 0.224 | 16 (37.2%) | 0.88 | 0.349 | 21 (48.8%) | 0.16 | 0.691 |
| Differentiation | ||||||||||
| Well | 51 | 44 (86.3%) | 20 (39.2%) | 33 (64.7%) | ||||||
| Moderately | 31 | 20 (64.5%) | 13 (41.9%) | 13 (41.9%) | ||||||
| Poorly | 37 | 24 (64.9%) | 7.04 | 0.029 | 18 (48.6%) | 0.79 | 0.672 | 15 (40.5%) | 6.47 | 0.039 |
| TNM staging | ||||||||||
| I, II | 39 | 25 (64.1%) | 17 (43.6%) | 16 (41.0%) | ||||||
| III, IV | 80 | 63 (78.8%) | 2.92 | 0.087 | 34 (42.5%) | 2.57 | 0.109 | 45 (56.3%) | 2.43 | 0.119 |
| Lymph node | ||||||||||
| Positive | 93 | 71 (76.3%) | 40 (43.0%) | 47 (50.5%) | ||||||
| Negative | 26 | 17 (65.4%) | 1.27 | 0.260 | 11 (42.3%) | 0.004 | 0.949 | 14 (53.8%) | 0.09 | 0.765 |